Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Peter ZauberMarlene Sabbath-Solitare

Abstract

Endometrial cancer (EC) results from the accumulation of numerous genetic abnormalities contributing to the progression from hyperplasia to EC. Information on these various genetic changes has been primarily derived from studying groups of either hyperplasias or cancers.We evaluated both hyperplastic and EC tissue obtained from the same surgical specimens for KRAS mutations, microsatellite instability (MSI), and mismatch repair gene methylation, and results were correlated between the paired hyperplastic tissue and EC. The aim was to determine if molecular alterations appearing in ECs might also be present in the premalignant (hyperplastic) region of the tumor. One hundred ninety-seven cases of EC with associated hyperplasia were evaluated. DNA samples were studied using primer sets for KRAS gene codons 12/13 and for MSI utilizing the Bethesda panel. Methylation testing was performed on specimens that were microsatellite unstable using the MRC Holland SALSA MS-MLPA methylation-specific DNA detection kit. Forty-one (20.8%) of 197 cancers demonstrated a KRAS mutation, with 35 (85.4%) of 41 accompanying hyperplasias also containing a KRAS mutation. Forty-five cancers (22.8%) were microsatellite unstable, with 38 (84.4%) of 45 acco...Continue Reading

References

Feb 1, 1983·Gynecologic Oncology·J V Bokhman
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yu-Zhen FengIkuo Konishi
Apr 28, 2009·American Journal of Obstetrics and Gynecology·Susan D ReedNoel S Weiss
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Taina T NieminenPäivi Peltomäki
Jan 13, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James V LaceyBryan Langholz
Apr 14, 2012·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Lisa M PetersonFabiola Medeiros
Jul 7, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Heejeong LeeChul Soo Park

❮ Previous
Next ❯

Citations

Feb 17, 2017·Carcinogenesis·Louis J M van der PuttenLeon F A G Massuger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.